// App-Quantinova.ai

10078 : A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Childrens Oncology Group phase I consortium trial.

Researchers

Presenter

  • Meredith K. Chuk

Principal Investigators

  • Brigitte C. Widemann

  • John Joseph Wright

  • Maya Lodish

  • Elizabeth Fox

  • Brenda Weigel

  • Susan Blaney

  • Charlotte H. Ahern

  • Joel M. Kim

Medical Centers

  • Department of Oncology, Mayo Clinic, Rochester, MN

  • Texas Childrens Cancer Center, Houston, TXPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MDUniversity of Minnesota, Minneapolis, MN

  • Baylor College of Medicine, Houston, TX

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • Urologic Oncology Branch, National Cancer Institute, Bethesda, MD

  • Children's Natl Medcl Ctr, Washington, DC

  • National Institute of Health, Bethesda, MD

  • National Cancer Institute, Rockville, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • High affinity nerve growth factor receptor

Drug/Treatment

  • Cabozantinib

Outcome

  • Indeterminate

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved